Ophthalmology Innovation Summit - Retina

Name: GenSight Biologics
Uploaded: 2018-07-23T15:22:00+00:00
Description: Barrett Katz, MD, Chief Medical Officer, GenSight Biologics, provides updates on its two gene therapy programs, GS010, which is in phase 3 trials for Leber hereditary optic neuropathy, and GS030 for retinitis pigmentosa.

OIS Retina: 2018

GenSight Biologics

Barrett Katz, MD

Show Description +

Barrett Katz, MD, Chief Medical Officer, GenSight Biologics, provides updates on its two gene therapy programs, GS010, which is in phase 3 trials for Leber hereditary optic neuropathy, and GS030 for retinitis pigmentosa.

Posted: 7/23/2018

Up Next

RFE Pharma

Alan Franklin, MD, PhD

EyePoint Pharmaceuticals

Tom Hadley

Zeiss

ZeaVision Holdings

Pinakin Davey, OD, PhD

iRenix

Stephen Smith, MD

Clearside Biomedical

Brion Raymond

Aerie Pharmaceuticals

Vince Anido Jr, PhD

Spark Therapeutics

Paulo Falabella, MD, PhD

Allegro

Vicken Karageozian, MD

Eyedaptic

Jay Cormier

Back to All Videos

GenSight Biologics

Barrett Katz, MD

Barrett Katz, MD, Chief Medical Officer, GenSight Biologics, provides updates on its two gene therapy programs, GS010, which is in phase 3 trials for Leber hereditary optic neuropathy, and GS030 for retinitis pigmentosa.

Posted: 7/23/2018